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Abstract: Cyclophellitol aziridine and its configurational and
functional isomers are powerful covalent inhibitors of retaining
glycosidases, and find application in fundamental studies on
glycosidases, amongst others in relation to inherited lysosomal
storage disorders caused by glycosidase malfunctioning. Few
direct and stereoselective aziridination methodologies are
known for the synthesis of cyclophellitol aziridines. Herein, we
Introduction
Glycosidases are enzymes involved in the degradation of com-
plex glycoconjugates in nature and are of relevance both in
biomedicine and biotechnology.[1] Many glycosidases follow a
two-step Koshland double displacement mechanism, which in-
volves a covalent enzyme-glycoside intermediate.[2] The active
site of such retaining glycosidases is usually composed of an
aspartic acid or glutamic acid, termed the catalytic acid/base,
and an aspartate/glutamate (or occasionally a tyrosine) termed
the nucleophile. In the first step of substrate hydrolysis, the
exocyclic oxygen is protonated by the acid/base residue. Next,
the catalytic nucleophile attacks at the anomeric carbon and
effects an SN2 displacement of the aglycon, yielding a covalent
enzyme–glycoside complex with inversion of the anomeric
stereochemistry.
In the second step, a water molecule is deprotonated by
the acid/base carboxylate and hydrolyses the enzyme-substrate
intermediate with a second inversion of the anomeric configu-
ration (Figure 1A).[3] Cyclitol aziridines can mimic the conforma-
tion of the oxocarbenium ion transition state and irreversibly
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present our studies on the scope of direct 3-amino-2-(trifluoro-
methyl)quinazolin-4(3H)-one-mediated aziridination on a vari-
ety of configurational and functional cyclohexenol isosters. We
demonstrate that the aziridination can be directed by an allylic
or homoallylic hydroxyl through H-bonding and that steric hin-
drance plays a key role in the diastereoselectivity of the reac-
tion.
Figure 1. A) Koshland double displacement mechanism of retaining -gluco-
sidases. B) Cyclophellitol aziridines are 4H3 transition-state mimics and inhibit
covalently and irreversibly retaining -glucosidases.
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inactivate glycosidases by covalently reacting with the nucleo-
philic carboxylate (Figure 1B). Based on this virtue and the fact,
as supported by several studies in recent years from our
group,[4] that covalent and irreversible inhibition is often both
very effective and highly selective, cyclitol aziridines and their
corresponding activity-based probes (ABPs) are highly useful
tools for chemical glycobiology research.[5]
An important step in the synthesis of cyclitol aziridine inhibi-
tors and ABPs involves the stereoselective aziridination of a suit-
able cyclohexene precursor.[6] In contrast to epoxidations, syn-
thetic methodologies for the direct and stereoselective
aziridination of alkenes are scarce.[7] Our previous work on the
synthesis of cyclophellitol aziridines relied mostly on either
intramolecular iodocyclization followed by aziridine formation
(Figure 2A)[5a,c,d] or Staudinger-type ring closure of 1,2-azido-
alcohols obtained from an epoxide precursor (Figure 2B).[5b] We
also investigated the use of O-(2,4-dinitrophenyl)hydroxylamine
(DPH) as nitrogen donor with Rh2(esp)2 as catalyst (Figure 2C).[8]
However, some limitations were encountered with these meth-
odologies. Although the iodocyclization/intramolecular substi-
tution sequence gives complete stereochemical control with
reasonable to good overall yields, this sequence is not an op-
Figure 2. Literature aziridination reactions on glycoside configured cyclohex-
enes. A) Stereoselective aziridination through cyclic imidates; B) Staudinger-
like ring closure of a 1,2-vicinal azido-alcohol obtained after nucleophilic ad-
dition of sodium azide to an epoxide intermediate; C) Direct synthesis of
unprotected N-H aziridines with DHP and Rh2(esp)2 catalyst; D) Stereoselec-
tive aziridination by means of Et-Q-NH2 as nitrogen donor; E) Exploration of
the aziridination scope by means of 3-aminoquinazolin-4(3H)-ones (R-Qs) on
various glycoside-configured cyclohexenols.
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tion when the desired aziridine has the opposite stereochemis-
try of that of the directing alcohol moiety. The rhodium-cata-
lyzed aziridination methodology appeared to be non-stereo-
selective and to proceed in relatively low yields,[8] while in the
Staudinger approach, purification can be challenging and over-
reduced amino-alcohols are occasionally generated as side
products (although the use of polymer-bound triphenylphos-
phine alleviates these shortcomings to certain extent[8b,9]).
In the late 1960s, Atkinson and co-workers described the
lead acetate mediated in situ oxidation of diverse hydrazines,
amongst which 3-aminobenzoxazolin-2-one was used as
aziridinating agent.[10] They initially proposed that nitrenes
could be formed as intermediates[10,11] which would react with
electrophilic and nucleophilic olefins to give the observed
aziridines. Atkinson et al. extensively re-examined the reactivity
of different substituted 3-aminoquinazolin-4(3H)-ones (Q-NH2s)
towards diverse olefins,[12] and concluded that N-acetoxy-
aminoquinazolones (Q-NHOAc) are the reactive intermediates,
rather than nitrenes.[13] Recently, the stereospecific aziridination
of a partially protected galacto-configured cyclohexene has
been described by Llebaria and co-workers based on the use of
3-amino-2-ethylquinazolin-4(3H)-one (Et-Q-NH2) and PhI(OAc)2
(PIDA). The thus formed -galacto-configured acetylated azir-
idine was employed in this study to produce N-aminoaziridine
based irreversible inhibitors (Figure 2D).[14] Inspired by this work
of Llebaria and co-workers we decided to explore the scope
of the direct olefin aziridination reaction by investigating the
reactivity of diverse aminoquinalozolin-4-ones towards differ-
ently configured and functionalized cyclohexenol substrates
(Figure 2E). As we show here, this reaction proved to be particu-
larly well suited for the synthesis of α-L-idose-configured cyclo-
phellitol aziridine, a key intermediate for the synthesis of new
α-L-iduronidase inhibitors and ABPs, as we recently reported in
a separate body of work.[15]
Results and Discussion
As the first research objective, D-gluco-configured cyclohexene
1a was used as starting material to screen the most promising
aminoquinazolinones described as nitrogen donors in the liter-
ature: 3-amino-2-ethylquinazolin-4(3H)-one (Et-Q-NH2), 3-
amino-2-(trifluoromethyl)quinazolin-4(3H)-one (CF3-Q-NH2) and
the chiral (S)-3-amino-2-(1-hydroxy-2,2-dimethylpropyl)quinazo-
lin-4(3H)-one (HO-Q-NH2), which all form in situ the reactive N-
acetoxy-aminoquinazolinones in the presence of PIDA. In line
with previous results,[12e] CF3-Q-NH2 gave superior yields (69–
75 % of 1b) when using cyclohexene 1a, PIDA and the quinazol-
one in a 1:2:2 ratio respectively and by forming the reactive N-
acetoxy-aminoquinazolinone at –78 °C prior to addition of the
olefin at –23 °C. Aziridine intermediate 1d was isolated in 54 %
yield when using HO-Q-NH2 as aziridination agent, whereas re-
action with Et-Q-NH2 returned starting material only
(Scheme 1). Notably, the -gluco-configured aziridine was
formed stereoselectively in a 1.5 mmol reaction scale, indicating
that hydrogen bonding from the homoallylic alcohol C7-OH
guides the incoming Q-NHOAc, in agreement with the mecha-
nistic proposal of Atkinson et al. (Scheme 2).[12a] These results
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led us to further investigate aziridinations with CF3-Q-NH2 on
different cyclohexene substrates.
Scheme 1. Stereoselective aziridination of cyclohexene 1a with 3-amino-2-
(trifluoromethyl)quinazolin-4(3H)-one (CF3-Q-NH2), chiral (S)-3-amino-2-(1-
hydroxy-2,2-dimethylpropyl)quinazolin-4(3H)-one (HO-Q-NH2) or 3-amino-2-
ethylquinazolin-4(3H)-one (Et-Q-NH2) as nitrogen donor. Reagents and condi-
tions: (i) PhI(OAc)2, R-Q-NH, DCM, r.t., 48 h.
Scheme 2. Proposed reaction transition state driven by H-bonding from the
homoallylic or allylic alcohols of gluco-cyclohexene 1a and 2a, respectively,
with N-acetoxy-3-amino-2-(trifluoromethyl)quinazolin-4(3H)-one (CF3-Q-
NHOAc, formed in situ) during the aziridination reactions, and subsequent
deprotection under Birch conditions. Starting material was recovered when
the reaction was performed on perbenzylated gluco-cyclohexene 3a. Rea-
gents and conditions: (i) PhI(OAc)2, CF3-Q-NH, DCM, r.t., 48 h; (ii) Li, NH3 (liq.),
THF, –60 °C, 1 h.
When gluco-configured cyclohexene 2a bearing a 4,6-benz-
ylidene acetal and an allylic alcohol at C-2 was used, α-aziridine
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2b was exclusively formed in 55 % yield, providing further sup-
port for H-bonding guided delivery of the aziridinating reagent
(Scheme 2). When perbenzylated gluco-cyclohexene 3a was
subjected to the same reaction conditions no conversion was
observed, indicating that the system is not reactive enough
without the hydrogen bonding guided delivery and/or that the
double bond, with relatively bulky substituents on either side
of the alkene, is too crowded to allow for an effective addition.
A similar pattern was observed with galacto-configured cyclo-
hexenes. Galacto-configured cyclohexene 4a could be stereo-
selectively transformed into -aziridine 4b while cyclohexene
5a afforded α-aziridine 5b in 61 % yield (Scheme 3). These ex-
amples again illustrate the impact of neighboring (homo)allylic
alcohol functionalities. Partially protected conduritol 6a was
also amenable to stereoselective aziridination, affording -azir-
idine 6b in 66 % yield, whereas the starting material was recov-
ered when the reaction was performed with perbenzylated con-
duritol 7a (Scheme 4).
Scheme 3. Proposed reaction transition state driven by H-bonding from the
homoallylic or allylic alcohols of galacto-cyclohexene 4a and 5a respectively,
with N-acetoxy-3-amino-2-(trifluoromethyl)quinazolin-4(3H)-one (CF3-Q-
NHOAc, formed in situ) during the aziridination reactions, and subsequent
deprotection under Birch conditions. Reagents and conditions: (i) PhI(OAc)2,
CF3-Q-NH, DCM, r.t., 48 h; (ii) Li, NH3 (liq.), THF, –60 °C, 1 h.
Scheme 4. Proposed reaction transition state driven by H-bonding from the
allylic alcohol of conduritol-cyclohexene 6a with N-acetoxy-3-amino-2-(tri-
fluoromethyl)quinazolin-4(3H)-one (CF3-Q-NHOAc, formed in situ) during the
aziridination reaction, and subsequent deprotection under Birch conditions.
Perbenzylated conduritol 7a does not react under the aziridination condi-
tions. Reagents and conditions: (i) PhI(OAc)2, CF3-Q-NH, DCM, r.t., 48 h; (ii) Li,
NH3 (liq.), THF, –60 °C, 1 h.
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In order to investigate whether an alcohol further away from
the alkene could guide the reagent to one of the diastereotopic
faces of the double bond, we examined the aziridination of
partially protected xylo-configured cyclohexene 8a. In this case
only -isomer 8b was obtained, indicating that the 4-OH is too
distal for a productive H-bond interaction and that the
aziridination takes place on the least hindered face of the dou-
ble bond, opposite of the C-2-benzyl ether (Scheme 5).
Scheme 5. Proposed reaction transition state driven by steric hindrance of
arabino-cyclohexene 8a with N-acetoxy-3-amino-2-(trifluoromethyl)qui-
nazolin-4(3H)-one (CF3-Q-NHOAc, formed in situ) during the aziridination re-
action, and subsequent deprotection under Birch conditions. Reagents and
conditions: (i) PhI(OAc)2, CF3-Q-NH, DCM, r.t., 48 h; (ii) Li, NH3 (liq.), THF, –60 °C,
1 h.
We finally explored aziridination of L-ido-configured cyclo-
hexenes in order to obtain α-L-ido-configured aziridines as po-
tential intermediates for the development of new iduronidase
inhibitors.[15] Partially protected cyclohexene 9a was not ame-
nable to aziridination, possibly because the primary alcohol di-
rects to the beta side while this region may be hindered by
the allylic benzyl ether. Considering that -D-xylo-configured
aziridine 8a was obtained without H-bonding, we postulated
H-bonding would not be essential for a satisfactory aziridina-
tion in case the double bond is readily accessible. To test this
hypothesis, the free alcohols in 9a were benzylated (benzyl
bromide, sodium hydride) to generate cyclohexene 10a. From
this fully protected cyclohexenol, α-L-aziridine 10b was ob-
tained in 43 % yield together with 32 % recovered starting ma-
terial after direct aziridination using CF3-Q-NHOAc as the nitro-
gen donor (Table 1, Scheme 6). The α-configuration of aziridine
10c was confirmed by comparison of the experimental 1H NMR
coupling constants with the corresponding calculated values
acquired from DFT calculations.[15]
Table 1. Aziridination reaction and subsequent Birch reduction on various
configured cyclohexenes 1a–10a.
Starting material CF3-Q-mediated aziridination Birch deprotection
1a -D-gluco 1b: 75 % -D-gluco 1c: 99 %
2a α-D-gluco 2b: 55 % α-D-gluco 2c: 96 %
3a –[a] –[a]
4a -D-galacto 4b: 48 % and 15 % S.M. -D-galacto 4c: 81 %
5a α-D-galacto 5b: 61 % α-D-galacto 5c: 85 %
6a -D-conduritol 6b: 66 % conduritol 6c: 99 %
7a –[a] –[a]
8a -D-xylo 8b: 45 % and 37 % S.M.[a] -D-xylo 8c: 96 %
9a –[a] –[a]
10a α-L-ido 10b: 43 % and 32 % S.M. α-L-ido 10c: 93 %
[a] Starting material (S.M.) recovered only.
In all cases, one step deprotection of the aziridine and hy-
droxyls in the aforementioned CF3-Q functionalized aziridine in-
termediates was achieved under Birch conditions using lithium
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Scheme 6. Partially protected cyclohexene 9a does not react under the azirid-
ination conditions. Proposed reaction transition state driven by steric hin-
drance of perbenzylated ido-cyclohexene 10a with N-acetoxy-3-amino-2-(tri-
fluoromethyl)quinazolin-4(3H)-one (CF3-Q-NHOAc, formed in situ) during the
aziridination reaction, and subsequent deprotection under Birch conditions.
and liquid ammonia at –78 °C. The reactions were quenched
with H2O and impurities derived from CF3-Q precipitated and
were removed by filtration. The cyclitol aziridines were finally
obtained in excellent yields after cation-exchange chromatogra-
phy with Amberlite H+ resin to eliminate the lithium hydroxide
salts (Table 1, 81–99 %).
Conclusions
We have explored direct aziridination of both, partially pro-
tected and fully protected, configurational cyclohexenol using
different substituted 3-aminoquinazolin-4(3H)-ones. From these
studies we identified 3-amino-2-(trifluoromethyl)quinazolin-
4(3H)-one (CF3-Q) as the superior aziridinating agent. Using this
reagent, direct aziridination reaction can be applied on diverse
glycoside configured cyclohexenes, and it appears that
aziridination can be directed by allylic or homoallylic hydroxyls
through H-bonding and that steric hindrance plays an essential
role in the diastereoselectivity of the reaction. With this in mind,
one could tune the cyclohexene scaffold depending on the de-
sired configuration of the target aziridine and thus, synthesize
diverse glycosidase inhibitors effectively in asymmetric fashion.
Experimental Section
General methods and materials: All reagents were of a commer-
cial grade and were used as received unless stated otherwise. Di-
chloromethane (DCM), tetrahydrofuran (THF) and N,N-dimethyl-
formamide (DMF) were stored over 4 Å molecular sieves, which
were dried in vacuo before use. All reactions were performed under
an argon atmosphere unless stated otherwise. Reactions were mon-
itored by analytical thin-layer chromatography (TLC) using Merck
aluminum sheets pre-coated with silica gel 60 with detection by
UV absorption (254 nm) and by spraying with a solution of
(NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·H2O (10 g/L) in 10 %
sulfuric acid followed by charring at ca. 150 °C or by spraying with
an aqueous solution of KMnO4 (7 %) and K2CO3 (2 %) followed by
charring at ca. 150 °C. Column chromatography was performed
manually or with a Biotage Isolera™ flash purification system using
silica gel cartridges (Screening devices SiliaSep HP, particle size 15–
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40 μm, 60A) in the indicated solvents. 1H NMR and 13C NMR spectra
were recorded on Bruker AV-400 (400/101 MHz) and Bruker AV-500
(500/126 MHz) spectrometer in the given solvent. Chemical shifts
are given in ppm relative to the chloroform residual solvent peak
or tetramethylsilane (TMS) as internal standard. Coupling constants
are given in Hz. All given 13C spectra are proton decoupled. The
following abbreviations are used to describe peak patterns when
appropriate: s (singlet), d (doublet), t (triplet), q (quadruplet), m
(multiplet), br (broad), Ar (aromatic), Cq, (quaternary carbon), Q
(quinazolinone). 2D NMR experiments (HSQC, COSY and NOESY)
were carried out to assign protons and carbons of the new struc-
tures. High-resolution mass spectra (HRMS) of intermediates were
recorded with a LTQ Orbitrap (Thermo Finnigan) and final com-
pounds were recorded with an apex-QE instrument (Bruker). Optical
rotations were measured on an Anton Paar MCP automatic polarim-
eter (Sodium D-line, λ = 589 nm). LC/MS analysis was performed on
an LCQ Advantage Max (Thermo Finnigan) ion-trap spectrometer
(ESI+) coupled to a Surveyor HPLC system (Thermo Finnigan)
equipped with a C18 column (Gemini, 4.6 mm × 50 mm, 3 μm parti-
cle size, Phenomenex) equipped with buffers A: H2O, B: acetonitrile
(MeCN) and C: 1 % aqueous TFA, or an Agilent Technologies 1260
Infinity LCMS with a 6120 Quadrupole MS system equipped with
buffers A: H2O, B: acetonitrile (MeCN) and C: 100 mM NH4OAc.
2,3-Bis-O-benzyl-D-gluco-cyclohexene (1a),[1] 7,4-O-benzylidene-D-
gluco-cyclohexene (2a),[16] perbenzylated D-gluco-cyclohexene
(3a),[4b] 2,3-Bis-O-benzyl-D-galacto-cyclohexene (4a),[17] 2,3-Bis-O-
benzyl-conduritol cyclohexene (6a),[18] perbenzylated conduritol
cyclohexene (7a),[16] 2,3-Bis-O-benzyl-D-xylo-cyclohexene (8a),[8b]
2,3-Bis-O-benzyl-L-ido-cyclohexene (9a)[15] and perbenzylated L-ido-
cyclohexene (10a),[15] 3-amino-2-ethylquinazolin-4(3H)-one,[19] (S)-
3-amino-2-(1-hydroxy-2,2-dimethylpropyl)quinazolin-4(3H)-one[20]
and 3-amino-2-(trifluoromethyl)-2,3-dihydroquinazolin-4(1H)-one[19]
were synthesized following procedures previously described and
their spectroscopic data are in agreement with those previously
reported.
Note: Numbering of proton peaks in cyclohexene and cyclitol azir-
idine derivatives is according to the numbering in Scheme 1.
(3aS,4S,5R,7aS)-5-(hydroxymethyl)-2-phenyl-3a,4,5,7a-tetra-
hydrobenzo[d][1,3]dioxol-4-ol (5a): (1S,2R,3S,6R)-6-(hydroxy-
methyl)cyclohex-4-ene-1,2,3-triol[9,21] was dissolved in dry DMF (2.0
mL) and dry MeCN (6.0 mL) in an inert atmosphere. CSA (173 mg,
0.74 mmol, 0.2 equiv.) was added to the solution, followed by
PhCH(OMe)2 (838 μL, 5.58 mmol, 1.5 equiv.). The reaction was
stirred overnight and then it was quenched with Et3N (100 μL,
0.23 mmol, 0.2 equiv.). The reaction mixture was extracted with
EtOAc (x2) and water. The combined organic layers were washed
with brine, dried with Na2SO4, filtered and concentrated in vacuo.
The product was purified by silica column chromatography (from
30 %→70 % EtOAc in pentane), affording cyclohexene 5a (598 mg,
2.41 mmol, 61 %). 1H NMR (500 MHz, CDCl3): δ = 7.45–7.37 (m, 2H,
2 × CH Ar), 7.33 (dd, J = 5.1, 2.0 Hz, 3H, 3 × CH Ar), 5.79 (dt, J =
10.1, 2.5 Hz, 1H, CH=CH), 5.55 (dd, J = 10.1, 2.1 Hz, 1H, CH=CH),
5.43 (s, 1H, CH-Ph), 4.41 (d, J = 7.2 Hz, 1H, CH-2), 4.29 (d, J = 1.4 Hz,
1H, CH-4), 4.16 (d, J = 11.6 Hz, 1H, CH-7a), 4.02 (dd, J = 11.7, 3.4 Hz,
1H, CH-7b), 3.59 (t, J = 7.3 Hz, 1H, CH-3), 3.33–3.14 (m, 2H, 2 × OH),
2.22 (s, 1H, CH-5). 13C NMR (126 MHz, CDCl3): δ 138.3 (Cq Ph), 130.8
(C-6), 129.2 (CH Ar), 128.4 (2 × CH Ar), 127.8 (C-1), 126.4 (2 × CH Ar),
101.2 (CHPh), 77.0 (C-4), 75.8 (C-3), 70.6 (C-2), 70.5 (C-7), 35.8 (C-5).
ESI-MS (m/z) : 248.9 [M + H+], HRMS: calcd. for [C14H17O4]+
249.11268, found 249.11220.
General procedure for aziridination: A solution of 3-amino-2-(tri-
fluoromethyl)-2,3-dihydroquinazolin-4(1H)-one (2 equiv.) in anhy-
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drous DCM (10 mL/mmol of cyclohexene) was added dropwise over
a period of 30 min to a stirred suspension of PhI(OAc)2 (PIDA)
(2 equiv.) in anhydrous DCM (5 mL/mmol of cyclohexene) at –78 °C.
The resultant mixture was stirred for additional 30 min and then
cooled to –23 °C and a solution of the corresponding cyclohexene
(1 equiv.) in DCM (1 mL/mmol of cyclohexene) was added dropwise
over a period of 15 min. The reaction mixture was stirred at –23 °C
for one hour and then the reaction was warmed to room tempera-
ture and stirred for 1–2 days. The mixture was diluted with EtOAc
and subsequently washed with 0.5 M aqueous KOH solution and
water. The combined water layers were extracted with EtOAc (× 2),
and the combined organic layers were dried with MgSO4, filtered
and concentrated in vacuo. Purification by column chromatography
(from pentane to pentane/EtOAc, 1:1) gave the desired aziridines.
-D-gluco-cyclitol CF3-Q-aziridine (1b): Obtained from cyclohex-
ene 1a (487 mg, 1.40 mmol) as an orange oil in 75 % yield (609 mg,
1.07 mmol). 1H NMR (400 MHz, CDCl3): δ = 8.15 (dt, J = 8.1, 1.1 Hz,
1H, CH Q), 7.86–7.80 (m, 2H, 2 × CH Q), 7.60 (ddd, J = 8.2, 5.0, 3.3 Hz,
1H, CH Q), 7.40–7.30 (m, 7H, 7 × CH Ar), 7.18 (t, J = 7.7 Hz, 2H,
2 × CH Ar), 6.99–6.91 (m, 1H, CH Ar), 4.97 (d, J = 11.2 Hz, 1H,
CHHPh), 4.75 (d, J = 11.4 Hz, 1H, CHHPh), 4.69 (dd, J = 11.4, 3.4 Hz,
2H, 2 × CHHPh), 4.42 (dd, J = 7.3, 3.4 Hz, 1H, CH-6), 4.03 (dd, J =
11.0, 6.7 Hz, 1H, CH-7a), 3.92 (d, J = 8.2 Hz, 1H, CH-2), 3.84 (dd, J =
11.0, 6.1 Hz, 1H, CH-7b), 3.70 (d, J = 7.3 Hz, 1H, CH-1), 3.50 (t, J =
10.0 Hz, 1H, CH-4), 3.38 (dd, J = 10.0, 8.2 Hz, 1H, CH-3), 3.16 (br s,
1H, OH), 2.96 (br s, 1H, OH), 2.14 (dtd, J = 10.0, 6.4, 3.4 Hz, 1H, CH-
5). 13C NMR (101 MHz, CDCl3): δ 161.0 (C=O), 143.9 (Cq Q), 143.4 (q,
J = 35.0 Hz, CCF3), 138.2 (Cq Ph), 137.4 (Cq Ph), 135.1, 129.4, 128.6,
128.6, 128.4, 128.0, 126.5 (10 × CH Ar, 4 × CH Q), 123.2 (Cq Q), 118.2
(q, JCF = 277.0 Hz, CF3), 84.1 (C-3), 79.8 (C-2), 75.1 (CH2Ph), 73.3
(CH2Ph), 69.3 (C-4), 63.7 (C-7), 43.6 (C-5), 40.5, 40.4 (C-1, C-6). HRMS:
calcd. for [C30H29F3N3O5]+ 568.20593, found 568.20551.
-D-gluco-cyclitol OH-Q-aziridine (1d): Obtained from cyclohex-
ene 1a (507 mg, 1.49 mmol) as an orange oil in 51 % yield (443 mg,
0.76 mmol). 1H NMR (400 MHz, CDCl3): δ = 8.21 (dd, J = 8.1 Hz, 1H,
CH Q), 7.81–7.73 (m, 1H, CH Q), 7.71–7.66 (m, 1H, CH Q), 7.54–7.47
(m, 1H, CH Q), 7.47–7.42 (m, 2H, 2 × CH Ar), 7.37–7.30 (m, 8H, 8 × CH
Ar), 5.06–5.01 (m, 2H, CHHPh, CH-2), 4.99 (d, J = 11.1 Hz, 1H, CHHPh),
4.79 (s, 1H, OH), 4.76–4.69 (m, 2H, 2 × CHHPh), 4.27–4.06 (m, 3H,
CH-7a,b, CH-3), 3.65–3.55 (m, 1H, OH), 3.50–3.42 (m, 2H, CH-4, tBu-
CH-OH), 3.39 (dd, J = 8.1, 3.5 Hz, 1H, CH-6), 2.76 (d, J = 8.0 Hz, 1H,
CH-1), 2.22 (ddt, J = 10.7, 7.4, 3.6 Hz, 1H, CH-5), 1.02 (s, 9H, 3 × CH3).
13C NMR (101 MHz, CDCl3): δ 159.4 (C=O), 144.5 (Cq Q), 138.1 (Cq
Ph), 137.3 (Cq Ph), 134.6, 128.7, 128.6, 128.5, 128.1, 128.0, 127.9,
127.8, 127.4, 127.0, 126.6 (10 × CH Ar, 4 × CH Q), 121.2 (Cq Q), 84.6
(tBu-CH-OH). 80.0 (C-3), 75.4 (CH2Ph), 74.9 (C-2), 72.6 (CH2Ph), 66.3
(C-4), 61.3 (C-7), 51.5 (C-1), 49.2 (C-6), 44.2 (C-5), 38.5 (C(CH3)3), 25.9
(3 × CH3). ESI-MS (m/z): 586.3 [M + H+].
α-D-gluco-cyclitol CF3-Q-aziridine (2b): Obtained from cyclohex-
ene 2a (40 mg, 0.161 mmol) as an orange oil in 55 % yield (43 mg,
0.089 mmol). 1H NMR (500 MHz, CDCl3): δ 8.21 (d, J = 7.7 Hz, 1H,
CH Q), 7.90–7.80 (m, 2H, 2 × CH Q), 7.62 (ddd, J = 8.2, 6.2, 2.1 Hz,
1H, CH Q), 7.50 (dd, J = 7.6, 2.1 Hz, 2H, 2 × CH Ar), 7.42–7.33 (m,
3H, 3 × CH Ar), 5.54 (s, 1H, CHPh), 4.47 (dd, J = 10.7, 4.7 Hz, 1H, CH-
7a), 4.10 (d, J = 7.2 Hz, 1H, CH-2), 4.06 (dd, J = 7.2, 4.5 Hz, 1H, CH-
1), 3.84 (dd, J = 11.8, 10.7 Hz, 1H, CH-7b), 3.73 (dd, J = 10.3, 7.8 Hz,
1H, CH-3), 3.66 (br s, 1H, OH), 3.45 (d, J = 7.2 Hz, 1H, CH-6), 3.30 (t,
J = 10.5 Hz, 1H, CH-4), 2.85 (br s, 1H, OH), 2.38 (dddd, J = 12.0, 10.5,
4.7, 1.8 Hz, 1H, CH-5). 13C NMR (126 MHz, CDCl3): δ 160.8 (C=O),
143.9 (Cq Q), 142.4 (q, J = 36.6 Hz, CCF3), 137.4 (Cq Ph), 135.4, 129.8,
129.4, 128.8, 128.5, 126.8, 126.3 (10 × CH Ar, 4 × CH Q), 122.7 (Cq
Q), 128.2 (q, JCF = 278.2 Hz, CF3), 102.3 (CHPh), 80.0 (C-4), 73.6 (C-
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3), 72.2 (C-2), 68.8 (C-7), 43.8 (C-1), 41.4 (C-6), 37.4 (C-5). HRMS: calcd.
for [C23H21F3N3O5]+ 476.1433, found 476.1423; calcd. for
[C23H20F3N3NaO5]+ 498.1252, found 498.1244.
-D-galacto-cyclitol CF3-Q-aziridine (4b): Obtained from cyclo-
hexene 4a (470 mg, 2.05 mmol) as an orange oil in 49 % yield
(225 mg, 1.00 mmol) and 15 % starting material recovered. [α]D20 =
+69.4 (c = 0.5, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 8.22–8.16 (d,
J = 7.6 Hz, 1H, CH Q), 7.88–7.80 (m, 2H, 2 × CH Q), 7.62 (ddd, J =
8.2, 6.3, 2.1 Hz, 1H, CH Q), 7.42–7.21 (m, 9H, CH Ar), 7.15–7.07 (m,
1H, CH Ar), 4.93 (d, J = 10.9 Hz, 1H, CHHPh), 4.78 (d, J = 11.6 Hz,
1H, CHHPh), 4.76 (d, J = 10.8 Hz, 1H, CHHPh), 4.67 (d, J = 11.8 Hz,
1H, CHHPh), 4.29 (d, J = 8.6 Hz, 1H, CH-2), 4.23 (dd, J = 11.6, 8.2 Hz,
1H, CH-7a), 4.10 (br s, 1H, CH-4), 3.99 (dd, J = 11.6, 5.8 Hz, 1H, CH-
7b), 3.94 (dd, J = 7.9, 3.0 Hz, 1H, CH-6), 3.53 (br s, 1H, OH), 3.45–
3.36 (m, 2H, CH-1, CH-3), 2.65 (d, J = 8.0 Hz, 1H, OH), 2.19 (br s, 1H,
CH-5). 13C NMR (101 MHz, CDCl3): δ 160.1 (C=O), 143.5 (Cq Q), 141.4
(q, J = 35.5 Hz, CCF3), 138.0 (Cq Ph), 137.9 (Cq Ph), 135.3, 129.8,
128.6, 128.5, 128.4, 128.3, 128.1, 127.9, 126.9 (10 × CH Ar, 4 × CH Q),
122.8 (Cq Q), 118.1 (q, JCF = 275.0 Hz, CF3), 82.9 (C-3), 77.5 (C-2),
74.8 (CH2Ph), 71.9 (CH2Ph), 67.3 (C-4), 61.9 (C-7), 49.1 (C-1), 44.0
(C-6), 41.0 (C-5). HRMS: calcd. for [C30H29F3N3O5]+: 568.2059, found
568.2061; calcd. for [C30H28F3N3NaO5]+: 590.1879, found 590.1882.
α-D-galacto-cyclitol CF3-Q-aziridine (5b): Obtained from cyclo-
hexene 5a (550 mg, 2.2 mmol) as an orange oil in 61 % yield
(643 mg, 1.35 mmol). 1H NMR (400 MHz, CDCl3): δ 8.18–8.09 (m, 1H,
CH Q), 7.80–7.70 (m, 2H, 2 × CH Q), 7.55 (ddd, J = 8.3, 6.4, 2.0 Hz,
1H, CH Q), 7.40 (dq, J = 5.2, 2.9 Hz, 2H, 2 × CH Ar), 7.34–7.23 (m,
3H, 3 × CH Ar), 5.39 (s, 1H, CHPh), 4.37–4.23 (m, 2H, CH-2, CH-7a),
4.14–4.03 (m, 2H, CH-4, CH-7b), 3.90 (dd, J = 7.7, 4.1 Hz, 1H, CH-1),
3.68–3.57 (m, 2H, CH-3, CH-4), 2.08 (s, 1H, CH-5). 13C NMR (101 MHz,
CDCl3): δ 160.3 (C=O), 143.6 (Cq Q), 141.8 (q, J = 36.0 Hz, CCF3),
137.9 (Cq Ph), 135.0, 129.5, 129.0, 128.4, 128.1, 126.6, 126.2 (5 × CH
Ar, 5 × CH Q), 122.4 (Cq Q), 114.0 (q, JCF = 277.8 Hz, CF3), 101.1
(CHPh), 77.5 (C-4), 72.9 (C-3), 69.9 (C-7), 68.2 (C-2), 47.7 (C-6), 46.5
(C-1), 34.3 (C-5). HRMS: calcd. for [C23H21F3N3O5]+ 476.14333, found
476.14255.
-D-conduritol CF3-Q-aziridine (6b): Obtained from cyclohexene
6a (300 mg, 0.72 mmol) as an orange oil in 66 % yield (305 mg,
0.47 mmol). 1H NMR (400 MHz, CDCl3): δ 8.17 (dd, J = 7.8, 1.2 Hz,
1H, CH Q), 7.92–7.79 (m, 2H, 2 × CH Q), 7.61 (ddd, J = 8.3, 5.2, 3.2 Hz,
1H, CH Q), 7.45–7.28 (m, 12H, 12 × CH Ar), 7.28–7.14 (m, 2H, 2 × CH
Ar), 7.07–6.96 (m, 1H, CH Ar), 4.97 (d, J = 11.3 Hz, 1H, CHHPh), 4.90–
4.81 (m, 2H, 2 × CHHPh), 4.79 (d, J = 11.2 Hz, 1H, CHHPh), 4.71 (dd,
J = 11.3, 6.6 Hz, 2H, 2 × CHHPh), 4.41 (dd, J = 7.2, 3.7 Hz, 1H, CH-
6), 3.99 (td, J = 7.0, 6.1, 2.9 Hz, 2H, CH-3, CH-5), 3.93 (d, J = 7.2 Hz,
1H, CH-1), 3.55–3.42 (m, 2H, CH-2, CH-4), 2.59 (br s, 1H, OH). 13C
NMR (101 MHz, CDCl3): δ 161.0 (C=O), 143.5 (q, J = 34.9 Hz, CCF3),
142.9, 138.6, 138.5 (3 × Cq Ph), 137.6, 135.2, 129.5, 128.7, 128.6,
128.5, 128.3, 128.1, 128.0, 127.8, 126.6 (15 × CH Ar, 4 × CH Q), 123.2
(Cq Q), 117.3 (q, JCF = 277.6 Hz, CF3), 83.6, 80.2, 79.8 (3 × CH), 75.8,
75.7, 73.9 (3 × CH2 Ph), 71.4 (CH), 42.6 (CH-6), 40.6 (CH-1). HRMS:
calcd. for [C36H33F3N3O5]+: 644.2372, found 644.2368; calcd. for
[C36H32F3N3NaO5]+: 666.2192, found 666.2189.
-D-xylo-cyclitol CF3-Q-aziridine (8b): Obtained from cyclohexene
8a (300 mg, 0.97 mmol) as an orange oil in 45 % yield (233 mg,
0.43 mmol) and 37 % starting material recovered (112 mg,
0.36 mmol). 1H NMR (400 MHz, CDCl3): δ 8.19 (dt, J = 8.0, 1.1 Hz,
1H, CH Q), 7.88–7.81 (m, 2H, 2 × CH Q), 7.65–7.58 (m, 1H, CH Q),
7.43–7.29 (m, 7H, 7 × CH Ar), 7.27–7.19 (m, 2H, 2 × CH Ar), 7.07–
7.00 (m, 1H, CH Ar), 4.99 (d, J = 11.2 Hz, 1H, CHHPh), 4.80 (d, J =
2.1 Hz, 2H, 2 × CHHPh), 4.67 (d, J = 11.2 Hz, 1H, CHHPh), 4.03–3.95
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(m, 2H, CH-2, CH-6), 3.77 (d, J = 7.2 Hz, 1H, CH-1), 3.65 (td, J = 10.5,
5.4 Hz, 1H, CH-4), 3.30 (dd, J = 10.0, 8.2 Hz, 1H, CH-3), 2.65–2.54 (m,
2H, CH-5a, OH), 1.74 (ddd, J = 14.2, 10.9, 3.5 Hz, 1H, CH-5b). 13C
NMR (101 MHz, CDCl3): δ 160.8 (C=O), 144.1 (Cq Q), 143.5 (q, J =
36.4 Hz, CCF3), 138.4, 137.7 (2 × Cq Ph), 135.0, 129.4, 128.7, 128.7,
128.5, 128.1, 128.0, 126.6 (10 × CH Ar, 4 × CH Q), 123.2 (Cq Q), 118.3
(q, JCF = 275.4 Hz, CF3), 84.63= (C-3), 80.4 (C-2), 75.1 (CH2Ph), 73.0
(CH2Ph), 65.7 (C-4), 41.4, 41.1 (C-1, C-6), 30.6 (C-5). HRMS: calcd. for
[C2 9H27F3N3O4 ] + : 538 .1954 , found 538 .1960 ; ca l cd . fo r
[C29H26F3N3NaO4]+: 560.1773, found 560.1779.
α-L-ido-cyclitol CF3-Q-aziridine (10b): Obtained from cyclohexene
10a (2.9 g, 5.57 mmol) as an orange oil in 43 % yield 1.79 g,
2.40 mmol). [α]D20 = +1.2 (c = 1, CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 8.25 (d, J = 7.9 Hz, 1H, CH Ar), 7.87 (d, J = 3.6 Hz, 2H, 2 × CH
Ar), 7.67–7.63 (m, 1H, CH Ar), 7.49–7.25 (m, 19H, 19 × CH Ar), 7.14
(t, J = 7.4 Hz, 1H, CH Ar), 4.87 (d, J = 11.1 Hz, 1H, CHHPh), 4.84 (s,
2H, 2 × CHHPh), 4.78 (d, J = 11.1 Hz, 1H, CHHPh), 4.74 (d, J = 11.6 Hz,
1H, CHHPh), 4.67–4.57 (m, 3H, 3 × CHHPh), 4.22 (d, J = 7.3 Hz, 1H,
CH-6), 4.06 (d, J = 7.0 Hz, 1H, CH-3), 4.00 (d, J = 7.4 Hz, 1H, CH-1),
3.98–3.96 (m, 1H, CHHPh), 3.78–3.69 (m, 3H, CH-2, CH-4, CHHPh),
2.99–2.93 (m, 1H, CH-5). 13C NMR (101 MHz, CDCl3): δ = 160.7 (C=
O), 144.0 (Cq Ar Q), 143.4 (q, J = 34.1 Hz, CCF3), 139.0, 138.6, 138.3,
138.1 (Cq Ar), 134.9, 129.3, 128.6, 128.5, 128.4, 128.0, 127.9, 127.8,
127.7, 127.6, 126.6 (20 × CH Ar, 4 × CH Q), 123.2 (Cq Q), 118.2 (q, J =
276.68 Hz, CF3), 80.7 (C-4/2), 80.2 (C-3), 76.0 (C-4/2), 75.2, 73.4, 73.2,
73.1 (4 × CH2Ph), 67.6 (C-7), 44.2 (C-6), 41.2 (C-1), 38.0 (C-5). HRMS:
calcd. for [C44H40F3N3O5]+ 748.29983, found 748.29901. HRMS:
calcd. for [C44H40F3N3NaO5]+ 770.28123, found 770.28076. Data in
agreement with those previously reported.[15]
General procedure for aziridine deprotection: Ammonia (10 mL/
mmol of starting material) was condensed at –60 °C. Lithium
(15 equiv.) was added and the mixture was stirred until the lithium
was completely dissolved and a bright blue solution was observed.
Then, a solution of protected aziridine dissolved in anhydrous THF
(5 mL/mmol) was added dropwise. The reaction mixture was stirred
for 1 h at –60 °C and subsequently quenched with MeOH and mil-
liQ-H2O. The solution was warmed to room temperature and stirred
until the ammonia was evaporated. The reaction crude was concen-
trated in vacuo, redissolved in MilliQ-H2O and filtered to remove
orange solid impurities from CF3-Q. The filtrate was neutralized with
Amberlite IR-120 H+ and the aziridine product bound to the resin
was washed with water (3 times) to remove Li salts and subse-
quently eluted with an aqueous 1M NH4OH solution, and concen-
trated under reduced pressure to afford the fully deprotected azir-
idine.
-D-gluco-cyclitol aziridine (1c): Obtained from aziridine 1b
(479 mg, 0.84 mmol) as an oil in 99 % yield (146 mg, 0.83 mmol).
1H NMR (400 MHz, D2O): δ 3.94 (dd, J = 10.9, 4.1 Hz, 1H, CH-7a),
3.70–3.58 (m, 2H, CH-7b, CH-2), 3.26 (dd, J = 10.2, 8.6 Hz, 1H, CH-
3), 3.02 (t, J = 10.1 Hz, 1H, CH-4), 2.57 (dd, J = 6.1, 3.4 Hz, 1H, CH-
6), 2.29 (d, J = 6.2 Hz, 1H, CH-1), 2.00 (m, 1H, CH-5). 13C NMR
(101 MHz, D2O): δ 76.9 (C-3), 72.1 (C-2), 67.7 (C-4), 61.8 (C-7), 43.1
(C-5), 34.4 (C-1), 32.5 (C-6). Data in agreement with those previously
reported.[22]
α-D-gluco-cyclitol aziridine (2c): Obtained from aziridine 2b
(104 mg, 0.22 mmol) as an oil in 96 % yield (37 mg, 0.21 mmol). 1H
NMR (400 MHz, D2O): δ 3.87–3.77 (m, 2H), 3.69 (dd, J = 11.1, 6.4 Hz,
1H), 3.28 (dd, J = 10.3, 8.6 Hz, 1H), 3.19 (t, J = 10.1 Hz, 1H), 2.52 (dd,
J = 6.4, 3.6 Hz, 1H), 2.30 (d, J = 6.4 Hz, 1H), 1.86–1.78 (m, 1H). Data
in agreement with those previously reported.[23]
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-D-galacto-cyclitol aziridine (4c): Obtained from aziridine 4b
(100 mg, 0.18 mmol) as an orange oil in 81 % yield (25 mg,
0.14 mmol). 1H NMR (500 MHz, D2O): δ 3.95 (d, J = 8.4 Hz, 1H, CH-
2), 3.83 (dd, J = 7.3, 1.0 Hz, 3H, CH2OH, CH-4), 3.40 (dd, J = 8.3,
2.4 Hz, 1H, CH-3), 2.44–2.36 (m, 1H, CH-1), 2.35–2.27 (m, 1H, CH-6),
2.22–2.11 (m, 1H, CH-5). 13C NMR (126 MHz, D2O): δ 76.0 (C-3), 70.4
(C-2), 70.1 (C-4), 61.2 (CH2), 39.2 (C-5), 34.4 (C-6), 31.9 (C-1). Data in
agreement with those previously reported.[9]
α-D-galacto-cyclitol aziridine (5c): Obtained from aziridine 5b
(622 mg, 1.31 mmol) as an oil in 85 % yield (195 mg, 1.11 mmol).
1H NMR (400 MHz, D2O): δ 4.05 (dd, J = 9.0, 4.3 Hz, 1H, CH-2), 3.82
(dt, J = 3.2, 1.6 Hz, 1H, CH-4), 3.77–3.65 (m, 2H, CH-7a,b), 3.32 (dd,
J = 9.0, 1.9 Hz, 1H, CH-3), 2.57 (dd, J = 6.4, 4.2 Hz, 1H, CH-1), 2.12
(dt, J = 6.3, 1.3 Hz, 1H, CH-6), 1.93 (tdd, J = 7.5, 3.2, 1.3 Hz, 1H, CH-
5). 13C NMR (126 MHz, D2O): δ 72.6 (C-3), 71.4 (C-4), 69.0 (C-2), 61.5
(C-7), 42.6 (C-5), 35.3 (C-1), 31.4 (C-6). Data in agreement with those
previously reported.[5b]
Conduritol aziridine (6c): Obtained from aziridine 6b (100 mg,
0.16 mmol) as an oil in 99 % yield (25 mg, 0.16 mmol). 1H NMR
(500 MHz, D2O): δ 3.90–3.84 (m, 1H, CH-3), 3.71–3.67 (m, 1H, CH-5),
3.25–3.18 (m, 2H, CH-2, CH-4), 2.61 (dd, J = 6.2, 3.6 Hz, 1H, CH-6),
2.34 (d, J = 6.2 Hz, 1H, CH-1). 13C NMR (126 MHz, D2O): δ 78.2 (C-
2/4), 74.7 (C-5), 74.1 (C-3), 73.5 (C-2/4), 37.9 (C-6), 37.4 (C-1). Data in
agreement with those previously reported.[24]
-D-xylo-cyclitol aziridine (8c): Obtained from aziridine 8b
(115 mg, 0.21 mmol) as an oil in 96 % yield (30 mg, 0.20 mmol). 1H
NMR (400 MHz, D2O): δ 3.61 (d, J = 8.3 Hz, 1H, CH-2), 3.34 (td, 1H,
J = 10.5, 5.4 Hz, CH-4), 3.15 (dd, J = 10.3, 8.4 Hz, 1H, CH-3), 2.42 (br
s, 1H, CH-6), 2.31 (ddd, J = 13.8, 5.4, 1.6 Hz, 1H, CH-5a), 2.17 (d, J =
6.1 Hz, 1H, CH-1), 1.66 (ddd, J = 14.0, 10.7, 3.3 Hz, 1H, CH-5b). 13C
NMR (101 MHz, D2O): δ 77.5 (C-3), 72.6 (C-2), 66.2 (C-4), 34.5 (C-
1), 31.3 (C-5), 30.8 (C-6). Data in agreement with those previously
reported.[8b]
α-L-ido-cyclitol aziridine (10c): Obtained from aziridine 10b (1.79
g, 2.39 mmol) as an oil in 93 % yield (389 mg, 2.22 mmol).
1H NMR (400 MHz, D2O): δ 2.47 (dd, J = 11.2, 4.4 Hz, 1H, CH-7a),
2.28–2.17 (m, 2H, CH-7b, CH-3), 2.11 (dd, J = 10.5, 5.6 Hz, 1H, CH-
4), 1.98 (dd, J = 10.5, 7.4 Hz, 1H, CH-2), 1.07 (d, J = 6.0 Hz, 1H, CH-
6), 1.01 (dt, J = 5.8, 5.1 Hz, 1H, CH-5), 0.77 (d, J = 6.0 Hz, 1H, CH-1).
13C NMR (101 MHz, D2O): δ = 76.0 (C-2), 75.2 (C-3), 70.1 (C-4), 62.2
(C-7), 43.5 (C-5), 36.9 (C-1), 36.3 (C-6). HRMS: calcd. for [C7H14NO4]+
176.09228, found 176.09175. Data in agreement with those previ-
ously reported.[15]
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